Photo by sharonmccutcheon from unsplash
Letter to the Editor TheHeart Failure Association of the European Society of Cardiology (HFA) and the International Cardio-Oncology Society (ICOS) recently proposed the use of a chartbased tool for the… Click to show full abstract
Letter to the Editor TheHeart Failure Association of the European Society of Cardiology (HFA) and the International Cardio-Oncology Society (ICOS) recently proposed the use of a chartbased tool for the baseline cardiovascular risk assessment of oncologic patients scheduled to receive anticancer treatments associated with cardiovascular toxicities. Among these drugs are antivascular endothelial growth factor (anti-VEGF) agents, which may cause arterial and venous thrombo-embolic events or heart failure.
Keywords:
patients scheduled;
vegf agents;
oncologic patients;
anti vegf;
cardiovascular toxicities;
scheduled receive
Journal Title: Journal of Cardiovascular Medicine
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Cardiovascular Medicine
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!